首页|持续肾替代疗法联合经皮冠状动脉介入治疗重症急性心肌梗死合并急性肾功能不全的效果

持续肾替代疗法联合经皮冠状动脉介入治疗重症急性心肌梗死合并急性肾功能不全的效果

扫码查看
目的 研究持续肾替代疗法(continuous renal replacement therapy,CRRT)联合经皮冠状动脉介入(percutaneous coronary intervention,PCI)治疗对重症急性心肌梗死(severe acute myocardial infarction,SAMI)合并急性肾功能不全患者生命体征、肝肾功能、并发症的影响.方法 选取 2021 年3 月—2023 年 4 月福建省立医院 60 例SAMI合并急性肾功能不全患者作为研究对象.按照随机数表法分为对照组和观察组,每组 30 例.对照组单纯行PCI治疗,观察组在对照组基础上联合CRRT治疗.比较 2 组生命体征、肝功能与肾功能指标及并发症发生情况.结果 观察组治疗后收缩压(systolic blood pressure,SBP)、舒张压(diastolic blood pressure,DBP)及心率(heart rate,HR)水平分别为(112.35±15.39)mmHg、(74.25±9.37)mmHg和(69.73±3.87)次/min,均低于对照组的(121.82±19.28)mmHg、(81.36±11.02)mmHg和(74.11±5.02)次/min(P= 0.039,P= 0.009,P<0.001).治疗后,观察组总胆红素(total bilirubin,TBIL)、谷草转氨酶(aspartate transaminase,AST)、尿素氮(blood urea nitrogen,BUN)及肌酐(creatinine,Cre)分别为(18.07±2.98)μmol/L、(35.87±5.23)U/L、(11.47±1.87)mmol/L、(79.48±7.25)μmol/L,均低于对照组的(21.32±3.14)μmol/L、(46.12±8.91)U/L、(13.08±2.08)mmol/L、(87.23±10.36)μmol/L(P<0.001,P<0.001,P=0.002,P=0.001).观察组并发症发生率(3.33%)低于对照组(26.67%)(P= 0.030).结论 CRRT联合PCI治疗能够更有效改善SAMI合并急性肾功能不全患者的生命体征,改善患者的肝功能及肾功能,同时减少并发症.
Effect of Continuous Renal Replacement Therapy Combined With Percutaneous Coronary Intervention in the Treatment of Severe Acute Myocardial Infarction Combined Acute Renal Insufficiency
Objective To investigate the effects of continuous renal replacement therapy(CRRT)combined with percutaneous coronary intervention(PCI)on vital signs,liver and kidney function,complication in patients with severe acute myocardial infarction(SAMI)combined acute renal insufficiency.Methods Sixty SAMI combined acute renal insufficiency patients in Fujian Provincial Hospital from March 2021 to April 2023 were selected as the research objects and divided into control group and observation group using a random number table method,with 30 patients in each group.The control group received simple PCI treatment,the observation group received CRRT treatment based on the control group.The vital signs,liver and kidney function indicators and complications of the two groups were compared.Results After treatment,systolic blood pressure(SBP),diastolic blood pressure(DBP),and heart rate(HR)in the observation group were(112.35±15.39)mmHg,(74.25±9.37)mmHg and(69.73±3.87)beats/min,respectively,which were lower than(121.82±19.28)mmHg,(81.36±11.02)mmHg,and(74.11±5.02)beats/min in the control group(P=0.039,P=0.009,P<0.001).After treatment,the total bilirubin(TBIL),aspartate transaminase(AST),blood urea nitrogen(BUN)and creatinine(Cre)in the observation group were(18.07±2.98)μmol/L,(35.87±5.23)U/L,(11.47±1.87)mmol/L,(79.48±7.25)μmol/L,which were lower than(21.32±3.14)μmol/L,(46.12±8.91)U/L,(13.08±2.08)mmol/L,(87.23±10.36)μmol/L in the control group(P<0.001,P<0.001,P=0.002,P=0.001).The incidence of complications in the observation group(3.33%)was lower than that in the control group(26.67%)(P=0.030).Conclusion The combination of CRRT and PCI can more effectively stabilize the vital signs of SAMI combined acute renal insufficiency patients,improve their liver and kidney function,and reduce the occurrence of complications.

severe acute myocardial infarctionacute renal insufficiencycontinuous renal replacement therapypercutaneous coronary interventionvital signsrenal functioncomplication

黄妍洁、周振和、陈煌

展开 >

福建省立医院急诊内科,福建 福州 350001

重症急性心肌梗死 急性肾功能不全 持续肾替代疗法 经皮冠状动脉介入 生命体征 肾功能 并发症

2024

中国卫生标准管理
《中国卫生标准管理》杂志社

中国卫生标准管理

影响因子:1.374
ISSN:1674-9316
年,卷(期):2024.15(1)
  • 13